Want to join the faculty at the Knight Cancer Institute? (OHSU/Joe Rojas-Burke). Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. My patients. The couple says their ultimate goal is to develop new effective therapies for cancer. What are the latest results? Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. CET membership is open to anyone at OHSU with an interest in advancing drug discovery and development. Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; Lookup NPI Numbers from the NPI Registry . S Kummar, ME Gutierrez, ER Gardner, X Chen, WD Figg, M Zajac-Kaye, European journal of cancer 46 (2), 340-347, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasPhase I Trial of ABT-888 with Topotecan, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Compressing drug development timelines in oncology using phase'0'trials, Wee1 kinase as a target for cancer therapy, Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain, A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudySD-101 Combined with Pembrolizumab in Advanced Melanoma, Cediranib for metastatic alveolar soft part sarcoma, Primary non-Hodgkin's lymphoma of the liver, Drug development in oncology: classical cytotoxics and molecularly targeted agents, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsPhase I Study of Olaparib with Cisplatin and Gemcitabine, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerAdenosine 2A Receptor Blockade as a Cancer Immunotherapy, Advances in using PARP inhibitors to treat cancer, Clinicopathologic Features of NonSmall-Cell Lung Cancer Harboring an, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies, Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Due to Covid-19 pandemic, the 2020 Symposium was postponed to 2021. 2001-2023 OHSU. & Kummar, S. Research output: Contribution to journal Comment/debate peer-review, Research output: Contribution to journal Review article peer-review, Research output: Contribution to journal Article peer-review, Powered by Pure, Scopus & Elsevier Fingerprint Engine 2023 Elsevier B.V, We use cookies to help provide and enhance our service and tailor content. Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute, speaks with staff members on Aug. 23, 2021. Shivaani Kummar, MBBS is an Oncologist. Shivaani Kummar. Clinical trials are research studies that test how well new medicines or treatments work in people. Kummar and Malhotra who have a high school-aged daughter and middle school-aged son met while she was faculty at Yale University. This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Accepting new patients Year; Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Seventeen patients with desmoid tumors received PF-03084014 150 mg orally twice a day in 3-week cycles. (OHSU/Joe Rojas-Burke), The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. The new early-phase research unit completes this expansion in the building. . This philanthropy-fueled research revolution is already saving lives. . We have a billion reasons why you should join us. 2001-2023 OHSU. (h.c.), Ph.D., FAACR. Before scheduling your appointment, we recommend you contact yourinsurancecompany to verify that the OHSU Health location or provider you plan to visit is included in your network. OHSU is an equal opportunity affirmative action institution. The Knight Cancer Institute's Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. Our patients in research studies can come in for their initial blood work and continue through their post treatment observation all in one place and are surrounded by a team of experts guiding them through the process.. Malhotras impressive background in drug development will be key to cultivating this new center, says Druker, also the JELD-WEN Chair of Leukemia Research at OHSU. Clinical trials Drug development oncology. He has the mindset and the clear vision to make that mindset a reality., Malhotra agrees: We speak the same language. 12 Reviews). Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute . By using this website, we will assume that you agree to the terms and conditions of our privacy policy. This new unit allows us to centralize everything in a setting designed for a patients convenience and comfort, said Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute. OHSU is an equal opportunity affirmative action institution. 23() 'Oregon Health & Science University Knight Cancer Institute(OHSU)' BAL0891 1 Shivaani Kummar (Principal Investigator, PI), OHSU 'Mary Crowley Cancer Research . In addition to her role as division head, Kummar will serve as co-director for a new center in the Knight Cancer Institute, theCenter for Experimental Therapeutics, which she will co-lead with Sanjay Malhotra, Ph.D. Kummar brings a wealth of experience in conducting clinical trials tailored to make early, informed decisions regarding the suitability of new drug candidates for further clinical investigation. (OHSU/Joe Rojas-Burke), Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for Health and Healing Building 2 on OHSU's South Waterfront campus, Aug. 23, 2021. Web Browser Accessibility, Oncology experts will head the Division of Hematology and Medical Oncology, direct new center for experimental therapeutics, Shivaani Kummar, M.D., and her husband Sanjay Malhotra, Ph.D., will co-lead the Knight Cancer institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. Shivaani Kummar, M.D., FACP Expertise Cancer Special focus Medical Oncology and Hematology Email this page Print this page About me Dr. Kummar is a cancer specialist whose focus is to bring new discoveries to the clinic, developing new treatments for cancer. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. (h.c.), Ph.D., FAACR. OHSU is an equal opportunity affirmative action institution. Keep me signed in. Patients and Methods. She accepts multiple insurance plans. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Very few institutions do it well, but OHSU truly gets it, Kummar says. Visit thebilling andinsurancesection of our sitefor more information. Early-phase trials are the first step in testing promising new medications and methods, and can offer patients early access to new and possibly better treatments. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. ( ) (MCI) 'BAL0891' 1 27 . 5 , IND transfer 4 . 23() 'Oregon Health . If you proceed in scheduling an appointment and your healthinsurancebenefits do not participate with OHSU providers, your out of pocket liability may be higher. The unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. Shivaani Kummar: STUDY00021766: . Shivaani Kummar Professor Professor, Knight Cancer Institute Knight Cancer Translational Oncology Program Email kummar @ ohsu. This center will be for the community, and we hope people will reach out to be a part of it. Administrative Coordinator, Felicia Feingersch Overall: 4.7 out of 5 She co-leads a team of 90 faculty members and along with her husband, Sanjay Malhotra, PhD, is focused on discovering new therapies for cancer and giving more people access to safe, experimental cancer treatments. Their partnership will be a perfect pairing.. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Share on email. These topic labels come from the works of this person. scripps institution of oceanography graduate programs; rosemont seneca advisors website Dr. Kummar specializes in the care and treatment of patients with cancer. Shivaani Kummar: STUDY00022986: An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer . Vol.49 No.07. Sanjay Malhotra, Ph.D. Shivaani Kummar, M.D., FACP To find better ways to treat patients. You may also qualify for Phase 1 Program trials. Shivaani Kummar. We are delighted she has chosen to join us, said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. Together they form a unique fingerprint. Palliative Care Administrative Assistant. Dr. A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, Clinical cancer research 18 (8), 2344-2351. She received her medical degree from Lady Hardinge Medical College and has been in practice for . Members receive periodic email communication about events, programming, news and funding opportunities. Local: (503) 228-1730 | Toll Free: (800) 462-6608 Hamburger Menu x Home Dr. Drukers vision for the field of translational oncology is similar to our vision of how to move discoveries from laboratories towardthe clinic. Password. Of that, $160 million was used for the Knight Cancer Research Building, which opened in 2018, and $40 million was used to build expanded capacity for clinical trial care in CHH2, which opened in 2019. Her husband is a synthetic medicinal chemist who leads the Center for Experimental Therapeutics dedicated to discovery new cancer treatments. Web Browser Accessibility, New early-phase clinical trial unit in the Center for Health and Healing Building 2 on South Waterfront centralizes care for cancer patients, provides more research opportunities, OHSU expands capacity for cancer clinical trials, OHSU Knight Cancer Institute: Understanding Cancer Clinical Trials, Expanding access to experimental cancer treatments in Oregon: Q&A with Shivaani Kummar, Severe respiratory illness season means boom times for OHSU virtual immediate care, OHSU leading effort to make cancer trials more inclusive, OHSU Child Life Specialist provides life-changing care to young patient living with chronic spinal condition, Making Hepatitis C care easier when treatment seems impossible. OHSU is an equal opportunity affirmative action institution. Early phase trials are conducted to test new treatments for cancer, while ensuring the highest standards of patient safety. shivaani kummar ohsu email. Across OHSU, doctors and researchers are reimagining early disease detection.